Interestingly, PML loss causes in prostate tumors a MAPK activation that in turn elicited the activation of a sterol regulatory element-binding protein (SREBP) prometastatic lipogenic program; in vivo targeting of SREBP using a fatostatin blocked tumor growth and metastatic activity [459]. The gene discussed is PML; the disease is neoplasm.